Cargando…
A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
BACKGROUND: Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand. METHODS: For this open-label, pragmatic, multicenter, no...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662794/ https://www.ncbi.nlm.nih.gov/pubmed/32725199 http://dx.doi.org/10.1093/cid/ciaa1084 |
_version_ | 1784613510468075520 |
---|---|
author | Anunnatsiri, Siriluck Chaowagul, Wipada Teparrukkul, Prapit Chetchotisakd, Ploenchan Tanwisaid, Kittisak Khemla, Supphachoke Narenpitak, Surapong Pattarapongsin, Moragot Kongsawasd, Wirod Pisuttimarn, Pornrith Thipmontree, Wilawan Mootsikapun, Piroon Chaisuksant, Seksan Chierakul, Wirongrong Day, Nicholas P J Limmathurotsakul, Direk |
author_facet | Anunnatsiri, Siriluck Chaowagul, Wipada Teparrukkul, Prapit Chetchotisakd, Ploenchan Tanwisaid, Kittisak Khemla, Supphachoke Narenpitak, Surapong Pattarapongsin, Moragot Kongsawasd, Wirod Pisuttimarn, Pornrith Thipmontree, Wilawan Mootsikapun, Piroon Chaisuksant, Seksan Chierakul, Wirongrong Day, Nicholas P J Limmathurotsakul, Direk |
author_sort | Anunnatsiri, Siriluck |
collection | PubMed |
description | BACKGROUND: Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand. METHODS: For this open-label, pragmatic, multicenter, noninferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 weeks and had no clinical evidence of active melioidosis. We randomly assigned patients to stop treatment (12-week regimen) or continue treatment for another 8 weeks (20-week regimen). The primary end point was culture-confirmed recurrent melioidosis within 1 year after enrollment. The noninferiority margin was a hazard ratio (HR) of 2.0. The secondary composite end point, combining overall recurrent melioidosis and mortality, was assessed post hoc. RESULTS: We enrolled 658 patients: 322 to the 12-week regimen and 336 to the 20-week regimen. There were 5 patients (2%) in the 12-week regimen and 2 patients (1%) in the 20-week regimen who developed culture-confirmed recurrent melioidosis (HR, 2.66; 95% confidence interval [CI], .52–13.69). The criterion for noninferiority of the primary event was not met (1-sided P = .37). However, all-cause mortality was significantly lower in the 12-week regimen group than in the 20-week regimen group (1 [.3%] vs 11 [3%], respectively; HR, 0.10; 95% CI, .01–.74). The criterion for noninferiority of the secondary composite end point, combining overall recurrent melioidosis and mortality, was met (1-sided P = .022). CONCLUSIONS: Based on the lower total mortality and noninferiority of the secondary composite end point observed, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis. CLINICAL TRIALS REGISTRATION: NCT01420341. |
format | Online Article Text |
id | pubmed-8662794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86627942021-12-13 A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial Anunnatsiri, Siriluck Chaowagul, Wipada Teparrukkul, Prapit Chetchotisakd, Ploenchan Tanwisaid, Kittisak Khemla, Supphachoke Narenpitak, Surapong Pattarapongsin, Moragot Kongsawasd, Wirod Pisuttimarn, Pornrith Thipmontree, Wilawan Mootsikapun, Piroon Chaisuksant, Seksan Chierakul, Wirongrong Day, Nicholas P J Limmathurotsakul, Direk Clin Infect Dis Online Only Articles BACKGROUND: Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand. METHODS: For this open-label, pragmatic, multicenter, noninferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 weeks and had no clinical evidence of active melioidosis. We randomly assigned patients to stop treatment (12-week regimen) or continue treatment for another 8 weeks (20-week regimen). The primary end point was culture-confirmed recurrent melioidosis within 1 year after enrollment. The noninferiority margin was a hazard ratio (HR) of 2.0. The secondary composite end point, combining overall recurrent melioidosis and mortality, was assessed post hoc. RESULTS: We enrolled 658 patients: 322 to the 12-week regimen and 336 to the 20-week regimen. There were 5 patients (2%) in the 12-week regimen and 2 patients (1%) in the 20-week regimen who developed culture-confirmed recurrent melioidosis (HR, 2.66; 95% confidence interval [CI], .52–13.69). The criterion for noninferiority of the primary event was not met (1-sided P = .37). However, all-cause mortality was significantly lower in the 12-week regimen group than in the 20-week regimen group (1 [.3%] vs 11 [3%], respectively; HR, 0.10; 95% CI, .01–.74). The criterion for noninferiority of the secondary composite end point, combining overall recurrent melioidosis and mortality, was met (1-sided P = .022). CONCLUSIONS: Based on the lower total mortality and noninferiority of the secondary composite end point observed, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis. CLINICAL TRIALS REGISTRATION: NCT01420341. Oxford University Press 2020-07-29 /pmc/articles/PMC8662794/ /pubmed/32725199 http://dx.doi.org/10.1093/cid/ciaa1084 Text en © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Online Only Articles Anunnatsiri, Siriluck Chaowagul, Wipada Teparrukkul, Prapit Chetchotisakd, Ploenchan Tanwisaid, Kittisak Khemla, Supphachoke Narenpitak, Surapong Pattarapongsin, Moragot Kongsawasd, Wirod Pisuttimarn, Pornrith Thipmontree, Wilawan Mootsikapun, Piroon Chaisuksant, Seksan Chierakul, Wirongrong Day, Nicholas P J Limmathurotsakul, Direk A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial |
title | A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial |
title_full | A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial |
title_fullStr | A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial |
title_full_unstemmed | A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial |
title_short | A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial |
title_sort | comparison between 12 versus 20 weeks of trimethoprim-sulfamethoxazole as oral eradication treatment for melioidosis: an open-label, pragmatic, multicenter, non-inferiority, randomized controlled trial |
topic | Online Only Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662794/ https://www.ncbi.nlm.nih.gov/pubmed/32725199 http://dx.doi.org/10.1093/cid/ciaa1084 |
work_keys_str_mv | AT anunnatsirisiriluck acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chaowagulwipada acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT teparrukkulprapit acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chetchotisakdploenchan acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT tanwisaidkittisak acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT khemlasupphachoke acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT narenpitaksurapong acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT pattarapongsinmoragot acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT kongsawasdwirod acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT pisuttimarnpornrith acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT thipmontreewilawan acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT mootsikapunpiroon acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chaisuksantseksan acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chierakulwirongrong acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT daynicholaspj acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT limmathurotsakuldirek acomparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT anunnatsirisiriluck comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chaowagulwipada comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT teparrukkulprapit comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chetchotisakdploenchan comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT tanwisaidkittisak comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT khemlasupphachoke comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT narenpitaksurapong comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT pattarapongsinmoragot comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT kongsawasdwirod comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT pisuttimarnpornrith comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT thipmontreewilawan comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT mootsikapunpiroon comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chaisuksantseksan comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT chierakulwirongrong comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT daynicholaspj comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial AT limmathurotsakuldirek comparisonbetween12versus20weeksoftrimethoprimsulfamethoxazoleasoraleradicationtreatmentformelioidosisanopenlabelpragmaticmulticenternoninferiorityrandomizedcontrolledtrial |